Skip to main content
OpenTrials

Clinical trial condition

Multiple Myeloma

Explore clinical trials studying Multiple Myeloma. Study availability and eligibility vary by location and protocol.

2,608 public trials 494 recruiting studies
Refine in advanced search Browse all conditions

Multiple Myeloma trial results

Completed

Frontline Therapy in de Novo Multiple Myeloma Patients Under 65

NCT01206205

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Centre François Baclesse Caen, France
  • University Hospital of Dijon, Hôpital des Enfants Dijon, France
  • University Hospital of Grenoble, Hôpital A.Michallon, BP 217 X Grenoble, France
  • University Hospital Of Lille, Hôpital Claude Huriez Lille, France
View Trial Details
Completed

Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT)

NCT00642395

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Service of Blood Deseases - South Hospital Amiens, France
  • Service of Clinical Hematology - Bocage Hospital Angers, France
  • Service of Clinical Hematology - Cote Basque Hospital Bayonne, France
  • Service of Clinical Hematology - Minjoz Hospital Besançon, France
View all 34 locations
View Trial Details
Completed

Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy

NCT01056276

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Los Robles Hospital and Medical Center Thousand Oaks, California, United States
  • Florida Cancer Specialists Fort Myers, Florida, United States
  • Hematology Oncology Clinic, LLP Baton Rouge, Louisiana, United States
  • Center for Cancer and Blood Disorders Bethesda, Maryland, United States
View all 13 locations
View Trial Details
Completed

A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma

NCT02072863

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Department of Clinical Therapeutics, University of Athens Athens, Attica, Greece
  • Ospedale Oncologico Regionale Rionero in Vulture, Potenza, Italy
  • Azienda Ospedaliera Universitaria S Martino Genova, Italy
  • AOU Maggiore della Carita, SCDU Heamatology Novara, Italy
View Trial Details
Completed

Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease

NCT01949532

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +27 more
Locations
  • Karmanos Cancer Institute Detroit, Michigan, United States
  • North Shore-LIJ Health System/Center for Advanced Medicine - North Shore University Hospital Lake Success, New York, United States
  • Gabrail Cancer Center Canton, Ohio, United States
  • Vanderbilt-Ingram Cancer Center, Henry-Joyce Cancer Clinic Nashville, Tennessee, United States
View all 13 locations
View Trial Details
Completed

Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma

NCT00530816

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Mayo Clinic Scottsdale Scottsdale, Arizona, United States
  • Tower Cancer Research Foundation Beverly Hills, California, United States
  • Therapeutic Research Institute of Orange County Laguna Hills, California, United States
  • Rocky Mountain Blood and Marrow Transplant Program Denver, Colorado, United States
View all 30 locations
View Trial Details

Related conditions